Tabelecleucel: Phê duyệt đầu tiên

Dierickx D, Pociupany M, Natkunam Y. Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment. Curr Opin Oncol. 2022;34(5):413–21. Ohmoto A, Fuji S. Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders. Blood Rev. 2021;49: 100807. Lv K, Yin T, Yu M, et al. Treatment advances in EBV related lymphoproliferative diseases. Front Oncol. 2022;12: 838817. Soldan SS, Messick TE, Lieberman PM. Therapeutic approaches to Epstein-Barr virus cancers. Curr Opin Virol. 2022;56: 101260. European Medicines Agency. Tabelecleucel: EPAR—public assessment report. 2022. https://www.ema.europa.eu/. Accessed 22 Jan 2023. Dharnidharka V, Thirumalai D, Jaeger U, et al. Clinical outcomes of solid organ transplant patients with Epstein-Barr virus-driven (EBV+) post-transplant lymphoproliferative disorder (PTLD) who fail rituximab plus chemotherapy: a multinational, retrospective chart review study [abstract no. 2528]. Blood. 2021;138(Suppl 1):2528. Sanz J, Storek J, Socié G, et al. Clinical outcomes of patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease following hematopoietic stem cell transplantation who fail rituximab: a multinational, retrospective chart review study [abstract no. 1454]. Blood. 2021;138(Suppl 1):1454. European Medicines Agency. Tabelecleucel: EU prescribing information 2022. https://www.ema.europa.eu/. Accessed 23 Jan 2023. Atara Biotherapeutics Inc. Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) receives European Commission Approval as first ever therapy for adults and children with EBV+ PTLD [media release]. 19 Dec 2022. https://investors.atarabio.com/. Atara Biotherapeutics Inc. Atara Biotherapeutics to receive additional near-term milestone payment under updated tabelecleucel (tab-cel®) commercialization agreement with Pierre Fabre [media release]. 28 Sep 2022. https://www.atarabio.com/. Atara Biotherapeutics inc. Atara Biotherapeutics and Pierre Fabre enter strategic collaboration to commercialize tabelecleucel (tab-cel®) [media release]. 4 Nov 2021. https://www.atarabio.com/. Atara Biotherapeutics Inc. Form 10-K. 2022. https://investors.atarabio.com/. Accessed 20 Jan 2023. Atara Biotherapeutics Inc. Atara Biotherapeutics and QIMR Berghofer Medical Research Institute announce exclusive license and research agreements [media release]. 21 Oct 2015. https://www.atarabio.com/. Atara Biotherapeutics Inc. Atara Biotherapeutics announces immunotherapy alliance with Memorial Sloan Kettering Cancer Center [media release]. 23 Sep 2014. https://www.atarabio.com/. Atara Biotherapeutics Inc. Atara Biotherapeutics exercises exclusive license to T-cell technology from Memorial Sloan Kettering Cancer Center [media release]. 15 Jun 2015. https://www.atarabio.com/. Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130(2):733–47. Mahadeo KM, Baiocchi R, Beitinjaneh A, et al. New and updated results from a multicenter, open-label, global phase 3 study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) following allogeneic hematopoietic cell (HCT) or solid organ transplant (SOT) after failure of rituximab or rituximab and chemotherapy (ALLELE) [abstract no. 4658]. Blood. 2022;140(Suppl 1):10374–6. Nikiforow S, Baiocchi R, Nasta S, et al. Clinical experience of tabelecleucel in patients with EBV+ primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease [abstract no. 1658]. In: 62nd Annual Meeting and Exposition of the American Society of Hematology. 2020. Prockop SE, Reshef R, Tsai DE, et al. Long-term outcomes of patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease following solid organ transplant or allogeneic hematopoietic cell transplant treated with tabelecleucel in a multicenter expanded access program study [abstract no. 81]. Biol Blood Marrow Transplant. 2020;26(3 Suppl):S61–2. Prockop S, Gamelin L, Dinavahi R, et al. Overall survival by best overall response with tabelecleucel in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease following solid organ or allogeneic hematopoietic cell transplant [abstract no. 887]. Blood. 2021;138(Suppl 1):887. Choquet S, Chaganti S, Uttenthal B, et al. Demographics and treatment outcomes in patients with EBV+ PTLD treated with off-the-shelf EBV-specific CTL under an ongoing expanded access program in Europe: first analyses [abstract no. 7530]. J Clin Oncol. 2022;40(16 Suppl):7530. Jiménez-Kurlander L, Behr G, Bunin N, et al. Updated efficacy and safety of tabelecleucel in patients with Epstein-Barr virus-positive (EBV+) leiomyosarcomas (LMS) [abstract no. 3349]. Blood. 2022;140(Suppl 1):7524–6. Prockop S, Dinavahi R, Navarro W, et al. A multicenter, multicohort, open-label, single-arm per cohort, phase II study to assess the efficacy and safety of tabelecleucel in patients with EBV-associated diseases using an adaptive two-stage study design [abstract no. 2551]. In: 62nd Annual Meeting and Exposition of the American Society of Hematology. 2020.